What the survey showed
Most Americans are not ready to hand pivotal medical calls to software. In Pew's June polling of 3,488 U.S. adults, 60% said they were uncomfortable with AI assisting their doctor on diagnoses or treatment planning. Views on patient outcomes were split, and nearly half expected their patient doctor relationship to get worse if AI is involved.
There is more openness to narrow, nonclinical tasks like translation. But once AI touches clinical judgment, hesitation rises.
Insurance, trust, and data risk
Skepticism gets sharper on insurance. Only 5% were comfortable with AI making claim decisions with no human review, and almost half did not want AI involved in those decisions at all.
Trust lines up clearly. Respondents said doctors are more likely to use AI in patients' best interests than health insurance companies, federal or state governments, tech firms, or hospital leadership. Privacy worries were prominent as well, with more than half saying AI could compromise the privacy of their health data.
Investors who learn to use thoughtful tools can gain a steady advantage over time. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
How views are shifting
Attitudes look similar to Pew's 2022 readout, though younger adults showed a broader negative turn toward AI in general. That comes even as Anthropic, OpenAI, and other large tech firms promote AI for healthcare and push for broad use. Yam said transparency will be key. "For ordinary Americans navigating a world where AI is increasingly part of healthcare, we see in our data that their views on AI in healthcare are not a binary 'thumbs up' versus 'thumbs down,'" she said. "Americans just want to be informed when AI is being used in their care."
Why it matters for your portfolio
In plain English: the current sentiment favors human oversight and clear disclosure. Companies advancing AI in care and coverage will likely face expectations around transparency and keeping clinicians involved, even as they tout efficiency.
Understanding new technologies helps investors make more confident, long term choices. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
